Assessing Adherence and Barriers to Long-Term Elimination Diet Therapy in Adults with Eosinophilic Esophagitis
The six-food elimination diet (SFED) is an effective treatment approach for eosinophilic esophagitis (EoE), but it can be challenging and affect patients’ quality of life.
Assess patients’ long-term adherence to SFED and potential factors influencing adherence.
EoE patients were recruited online via multiple platforms. Patients were classified as reaching the maintenance stage if they responded to SFED and identified specific trigger foods by reintroduction. Maintenance stage patients were categorized into those actively following the elimination diet (ACTIVE) and those no longer on their prescribed diet (FORMER). Participants completed a study-specific questionnaire assessing patient experiences related to SFED use.
Forty-two participants were identified as having reached the SFED’s maintenance stage. 57% (24/42) of the maintenance stage patients were ACTIVE users. FORMER users rated the SFED’s effectiveness at treating symptoms (5.45 ± 3.96, 10 max.) lower than ACTIVE users (8.29 ± 2.76, p = .02). A greater percentage of FORMER users (100%) agreed social situations create challenges in following the diet compared to ACTIVE users (67%, p < .05). Anxiety related to SFED was also higher among FORMER users (64%) compared to ACTIVE users (21%, p < .01). Both ACTIVE (95.8%) and FORMER (81.8%, NSS) users would recommend the elimination diet to other EoE patients.
Understanding SFED adherence is multifactorial and complex. Factors influencing SFED adherence during long-term maintenance with diet therapy include diet effectiveness, social situations, and diet-related anxiety. Despite a lower than expected long-term adherence to maintenance of an elimination diet, the majority would recommend diet therapy as a treatment to other EoE patients.
KeywordsEosinophilic esophagitis Gastroesophageal reflux disease Dysphagia Food allergy Esophageal stricture Esophagitis
Gastroesophageal reflux disease
Proton pump inhibitor
Dr. Hirano would like to acknowledge grant support from the NIH Consortium of Eosinophilic Gastrointestinal disease Researchers (NIH U54AI117804), which is part of the Rare Disease Clinical Research Network, an initiative of the Office of Rare Disease Research funded through a collaboration between NIAID, NIDDK and NCATS.
RW and IH helped in project conception, study design, data collection/interpretation, data analysis, manuscript drafting, and critical revision; BD, AZ, and NG contributed to study design and critical revision; TT helped in project conception, study design, data collection/interpretation, data analysis, manuscript drafting, supervision, and critical revision.
Compliance with ethical standards
Conflict of interest
None of the authors have potential conflicts related to this manuscript. Ikuo Hirano is a consultant and has received research funding from Adare, Shire, Regeneron, and Receptos. Tiffany Taft has served as a speaker for Janssen and Abbvie and Bethany Doerfler for Nutricia North America and Allergan’s IBS counsel.
- 5.Dellon ES. Diagnosis and management of eosinophilic esophagitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2012;10:1066–1078.Google Scholar
- 7.Liacouras CA, Spergel JM, Ruchelli E, et al. Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2005;3:1198–1206.Google Scholar
- 8.Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2008;6:165–173.Google Scholar
- 12.Kagalwalla AF, Sentongo TA, Ritz S, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4:1097–1102.Google Scholar